LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

Bright Health to Host Third Quarter 2023 Earnings Conference Call on November 7, 2023

October 13, 2023 | Last Trade: US$5.08 1.54 -23.26

MINNEAPOLIS / Oct 13, 2023 / Business Wire / Bright Health Group, Inc. ("Bright Health") (NYSE: BHG), the technology enabled, value-driven healthcare company, today announced it will report Third Quarter financial results before the financial markets open on Tuesday, November 7, 2023, followed by a conference call at 8:00 AM Eastern Time.

To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call.

A webcast of the earnings call may also be accessed via Bright Health’s Investor Relations page at investors.brighthealthgroup.com. The company suggests participants for the conference call dial in at least 15 minutes in advance of the call. A recording of the earnings call and presentation will be available on Bright Health’s Investor Relations page following the call.

About Bright Health Group

Bright Health Group is a technology enabled, value-driven healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in Florida, Texas and California, some of the largest markets in healthcare where 26% of the U.S. aging population call home. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page